Cargando…
Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) has been rarely reported because of its low incidence. The optimal treatment plan for patients with relapsed/refractory PB-DLBCL remains controversial. In this study, we present a case of a 57-year-old patient with refractory PB-DLBCL to better u...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810803/ https://www.ncbi.nlm.nih.gov/pubmed/36619626 http://dx.doi.org/10.3389/fmed.2022.989590 |
_version_ | 1784863384297013248 |
---|---|
author | Wu, Zhiya Teng, Yue Wu, Jianqiu Zhang, Honglu Peng, Weiwei Meng, Cheng Tang, Weiyan Feng, Jifeng |
author_facet | Wu, Zhiya Teng, Yue Wu, Jianqiu Zhang, Honglu Peng, Weiwei Meng, Cheng Tang, Weiyan Feng, Jifeng |
author_sort | Wu, Zhiya |
collection | PubMed |
description | Primary bone diffuse large B-cell lymphoma (PB-DLBCL) has been rarely reported because of its low incidence. The optimal treatment plan for patients with relapsed/refractory PB-DLBCL remains controversial. In this study, we present a case of a 57-year-old patient with refractory PB-DLBCL to better understand this disease. The patient developed lumbosacral/low extremity pain. A lumbar magnetic resonance imaging (MRI) revealed skeletal lesions with osteolysis in L4-L5 and S1. With the failure of multi-line chemotherapy, the patient developed paralysis of both lower limbs. 18-Fluorinefluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and MRI showed new lesions in the femoral head, cervical and thoracic vertebrae. We tried to treat the patient with adjuvant radiotherapy and 10 courses of high-dose methotrexate (HD-MTX)-based monotherapy, after which the patient was able to walk and achieved complete remission (CR). To the best of our knowledge, this is the first attempt to use local radiotherapy combined with an HD-MTX regimen successfully for the treatment of refractory PB-DLBCL. |
format | Online Article Text |
id | pubmed-9810803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98108032023-01-05 Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report Wu, Zhiya Teng, Yue Wu, Jianqiu Zhang, Honglu Peng, Weiwei Meng, Cheng Tang, Weiyan Feng, Jifeng Front Med (Lausanne) Medicine Primary bone diffuse large B-cell lymphoma (PB-DLBCL) has been rarely reported because of its low incidence. The optimal treatment plan for patients with relapsed/refractory PB-DLBCL remains controversial. In this study, we present a case of a 57-year-old patient with refractory PB-DLBCL to better understand this disease. The patient developed lumbosacral/low extremity pain. A lumbar magnetic resonance imaging (MRI) revealed skeletal lesions with osteolysis in L4-L5 and S1. With the failure of multi-line chemotherapy, the patient developed paralysis of both lower limbs. 18-Fluorinefluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and MRI showed new lesions in the femoral head, cervical and thoracic vertebrae. We tried to treat the patient with adjuvant radiotherapy and 10 courses of high-dose methotrexate (HD-MTX)-based monotherapy, after which the patient was able to walk and achieved complete remission (CR). To the best of our knowledge, this is the first attempt to use local radiotherapy combined with an HD-MTX regimen successfully for the treatment of refractory PB-DLBCL. Frontiers Media S.A. 2022-12-21 /pmc/articles/PMC9810803/ /pubmed/36619626 http://dx.doi.org/10.3389/fmed.2022.989590 Text en Copyright © 2022 Wu, Teng, Wu, Zhang, Peng, Meng, Tang and Feng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Wu, Zhiya Teng, Yue Wu, Jianqiu Zhang, Honglu Peng, Weiwei Meng, Cheng Tang, Weiyan Feng, Jifeng Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report |
title | Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report |
title_full | Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report |
title_fullStr | Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report |
title_full_unstemmed | Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report |
title_short | Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report |
title_sort | clinical use of hd-mtx monotherapy in a rare case of refractory primary bone diffuse large b-cell lymphoma with long-term survival after local radiotherapy: a case report |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810803/ https://www.ncbi.nlm.nih.gov/pubmed/36619626 http://dx.doi.org/10.3389/fmed.2022.989590 |
work_keys_str_mv | AT wuzhiya clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport AT tengyue clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport AT wujianqiu clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport AT zhanghonglu clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport AT pengweiwei clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport AT mengcheng clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport AT tangweiyan clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport AT fengjifeng clinicaluseofhdmtxmonotherapyinararecaseofrefractoryprimarybonediffuselargebcelllymphomawithlongtermsurvivalafterlocalradiotherapyacasereport |